Professor Georgina Long AO
BSc PhD MBBS FRACP FAHMS AAHMS FAA FASCO
Medical Director & Medical Oncologist
Professor Georgina Long AO, BSc (Hons1, UM) PhD MBBS (Hons) FRACP FAHMS AAHMS FAA FASCO, is Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on immuno-oncology and targeted therapies in melanoma. She is principal investigator on phase I, II and III clinical trials in (neo)adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance.
In recognition of her ground-breaking research and work, Professor Long was named 2024 Australian of the Year and was awarded prestigious Fellowships with the American Society for Clinical Oncology (2025), the Australian Academy of Science (2024) and the Australian Academy of Health and Medical Sciences (2017), the latter awarding her the Outstanding Female Research Medal (2021). Professor Long was appointed as an Officer of the Order of Australia (2020) and has received numerous awards, including Fulbright U.S. Mission Australia Award for Leadership Excellence (2024), Estela Medrano Melanoma Award (2024), ESMO Women for Oncology Award (2023), Sydney Local Health District/Sydney Research 2022 Research Excellence Award (2022) the prestigious Ramaciotti Medal for Biomedical Research (2021), Vice Chancellor’s Award for Excellence Award for Outstanding Research (2021), University of Sydney (2021), Research Australia GSK Research Excellence Award (2018) and the Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research (2016). She has a number of CINSW Premiers Awards, including: the Outstanding Cancer Researcher (2018), the Excellence in Translational Cancer Research Award (2017), the Wildfire Award for the most highly-cited, original, peer-reviewed article published (2011, 2014, 2016, 2017, 2018, 2019 & 2020), and in 2013 she was named the Outstanding Cancer Research Fellow. She is a Clarivate highly-cited Researcher from 2017, with an H index of 155.
Professor Long is the author of over 610 peer-reviewed publications in clinical and translational research in melanoma, including the New England Journal of Medicine, Lancet, Lancet Oncology, Science, Nature, Nature Medicine, Journal of Clinical Oncology and Cancer Discovery. Professor Long has presented her work at international conferences and meetings on more than 300 occasions. She was President for the prestigious international Society for Melanoma Research (President 2018-2020), is a member and Chair of the ASCO (2015-2017) and ESMO (2017-2020 & 2026 – 2029) Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, and is member of both the ASCO Plenary Series and ASCO AGM Education committees (2021-2024), Scientific Co-Chair for ESMO Asia (2024) and EADO (2026), she is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.
Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.
Prof Long Recent News
Prof Long Recent Publications
Thompson JR, Lai-Kwon J, Morton RL, Guminski AD, Gonzalez M, Atkinson V, Sandhu S, Brown MP, Menzies AM, McArthur GA, Lo SN, Long GV, Bartula I. Immunotherapy, (May 2 2023), doi:10.2217/imt-2022-0262.
Gjorup CA, Pires da Silva I, Martin L, Stretch JR, Scolyer RA, Long GV, Hong A. Melanoma Research, (Aug 03 9900): 10.1097/CMR.0000000000000905, doi:10.1097/cmr.0000000000000905.
Khattak A, Carlino M, Meniawy T, Ansstas G, Medina T, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran T, Cowey C, Pecora A, Segar J, Atkinson V, Gibney GT, Luke J, Thomas S, Buchbinder E, Hou P, Zhu L, Zaks T, Brown M, Aanur P, Meehan RS, Weber JS. Cancer Research, 83, no. 8_Supplement, (May 29 2023): CT001-CT01, doi:10.1158/1538-7445.Am2023-ct001.
Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GV. Nature Medicine, (May 16 2023), doi:10.1038/s41591-023-02336-1. TOP 1%
Zarif TE, Nassar AH, Adib E, Fitzgerald BG, Huang J, Mouhieddine TH, Rubinstein PG, Nonato T, McKay RR, Li M, Mittra A, Owen DH, Baiocchi RA, Lorentsen M, Dittus C, Dizman N, Falohun A, Abdel-Wahab N, Diab A, Bankapur A, Reed A, Kim C, Arora A, Shah NJ, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Ghazal BA, Saeed A, Drolen C, Lechner MG, Drakaki A, Baena J, Nebhan CA, Haykal T, Morse MA, Cortellini A, Pinato DJ, Pria AD, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Nana FA, Lopetegui-Lia N, Dima D, Dobbs RW, Funchain P, Saleem R, Woodford R, Long GV, Menzies AM, Genova C, Barletta G, Puri S, Florou V, Idossa D, Saponara M, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Reid EG, Chiao EY, Sharon E, Johnson DB, Ramaswami R, Bower M, Emu B, Marron TU, Choueiri TK, Baden LR, Lurain K, Sonpavde GP, Naqash AR. Journal of Clinical Oncology, (May 16 2023): JCO.22.02459, doi:10.1200/jco.22.02459. TOP 10%
Lee R, Mandala M, Long GV, Eggermont AMM, van Akkooi ACJ, Sandhu S, Garbe C, Lorigan P. European Journal of Cancer, (May 08 2023), doi:https://doi.org/10.1016/j.ejca.2023.05.003.
Esmee P. Hoefsmit, Franziska Völlmy, Elisa A. Rozeman, Irene L. M. Reijers, Judith M. Versluis, Liesbeth Hoekman, Alexander C. J. van Akkooi, Georgina V. Long, Dirk Schadendorf, Reinhard Dummer, Maarten Altelaar, Christian U. Blank. Cancer Research Communications 2023; https://doi.org/10.1158/2767-9764.CRC-23-0015
Long GV, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Salman P, Gutierrez EC, Rutkowski P, Gogas HJ Lao CD, De Menezes JJ, Dalle S, Arance A, Grob J-J, Keidel S, Shaikh A, Sobiesk AM, Dolfi S, Tawbi HA, NEJM Evidence, 2023 Mar 22, doi:10.1056/EVIDoa2200239
Schadendorf D, Tawbi H, Lipson EJ, Hodi FS, Rutkowski P, Gogas H, Lao CD, Grob J-J, Moshyk A, Lord-Bessen J, Hamilton M, Guo S, Shi L, Keidel S, Long GV, Eur J Cancer, 2023 Mar 22; doi: httpsL//doi.org/10.1016/j.ejca.2023.03.014
Ong J-S, Seviiri M, Dusingize JC, Han X, Shi J, Olsen CM, Neale RE, Thompson JF, Saw RPM, Shannon K, Mann G, Martin NG, Medland S, Gordon SG, Scolyer RA, Long GV, Iles MM, Landi MT, Whiteman DC, MacGregor S, Law MH. “Uncovering the complex relationship between balding and skin cancers in men.” Nature Comm, (Mar 20 2023).
ZERO DEATHS FROM MELANOMA
Suzanne Sherwood says:
Steve Cole says:
Catherine Mardell says: